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The combination of indomethacin, caffeine, and prochlorperazine (hereinafter IndoProCaf) repre-
sents an effective antimigraine drug available on the Italian market. The aim of this study was to
test the efficacy of the three active principles alone and in combination in reverting hyperalgesia.
Hyperalgesia was induced by morphine withdrawal in mice treated with morphine for 15 days and
then made hyperalgic by morphine substitution with water. This study showed that indomethacin
0.3 mg kg−1, i.p.; caffeine 0.1 and 0.3 mg kg−1, i.p.; and prochlorperazine 0.1 mg kg−1, i.p.; as well
as the combination of the three active principles, were able to revert morphine withdrawal induced
hyperalgesia, causing a statistically significant increase of pain threshold in hyperalgic mice. In a sec-
ond model, hyperalgesia was induced by the i.p. injection of a 0.3% solution of acetic acid in mice
and was evaluated counting the number of abdominal constrictions. Indomethacin (0.1 mg kg−1,
i.p.), caffeine (0.3 mg kg−1, i.p.), and prochlorperazine (0.1 mg kg−1, i.p.) reduced the number of
abdominal constrictions, while the combination of the three active principles was able to abolish
almost completely the abdominal constrictions, with a significantly higher efficacy compared to
the single active principles. In both models, indomethacin, caffeine, and prochlorperazine reverted
hyperalgesia at dosages 10 times lower than the corresponding analgesic ones. These data provide
the pharmacologic evidence of the efficacy of IndoProCaf in reverting hyperalgesia, a condition of
reduction of pain threshold similar to that occurring in migraine.
© 2002 Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
Migraine is a chronic condition characterized by episodic
attacks of headache commonly associated with various
combinations of nausea, vomiting, photophobia, and
phonophobia. It is a common disorder with 1-year preva-
lence estimates of around 10–12%, age- and gender-
dependent and 2–3 times more common in women than in
men [1]. Several different theories on migraine etiopathol-
ogy have been developed along the years and up to now
none of the hypotheses are able to explain all the clinical
and physiopathological aspects of migraine. Moreover, all
the experimental models of migraine implemented until
now are almost exclusively in vitro and the pharmacolog-
ical screening of potential antimigraine drugs is preva-
lently carried out on vascular isolated preparations [2].
∗Corresponding author. Medical Department, Solvay Pharma S.p.A., Via
della Liberta` 30, 10095 Grugliasco Torino, Italy.
E-mail: carla.uslenghi@solvay.com
Considering that in vivo models of migraine were not
available, an experimental mouse model correspondent to
migraine human pain was set up [3]. The model was based
on the observation that morphine withdrawal syndrome is
characterized by a hyperalgesia very similar to the reduc-
tion of pain threshold characteristic of migraineurs [4].
Previous experiments have shown that drugs used for the
treatment of migraine as sumatriptan and ergotamine are
effective in the model of hyperalgesia induced by mor-
phine withdrawal with their antihyperalgic effect showing
up at doses also 300 times lower for sumatriptan and 50
times lower for ergotamine compared to the correspondent
analgesic ones [3, 5, 6]. The above-mentioned drugs re-
sulted therefore active in this test of hyperalgesia at doses
corresponding more to the ones used in clinical practice
for the treatment of migraine.
Our personal experiences showed that the antihyperal-
gic activity of sumatriptan and ergotamine was confirmed
also in another model of hyperalgesia induced through the
intraperitoneal (i.p.) injection of a 0.3% solution of acetic
1043-6618/02/$ – see front matter © 2002 Elsevier Science Ltd. All rights reserved.
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acid. The correspondence of the active doses in the two
experimental models and the evidence that potent anal-
gesic drugs as morphine, which is not useful in the treat-
ment of migraine, are not active in the 0.3% solution of
acetic acid abdominal constriction test, also testify that
this test is a valid in vivo migraine model.
The combination of indomethacin, caffeine, and pro-
chlorperazine (Solvay Pharma S.p.A., Grugliasco, Torino,
Italy) is an effective antimigraine drug available on the
Italian market, where it is the most popular and used an-
timigraine treatment (IMS data). The aim of this study was
to investigate if the three active principles alone and in
combination were able to revert the morphine withdrawal




Male albino mice (20–25 g) from Morini (San Polo
d’Enza, Italy) were used. All experiments were carried
out according to the guidelines of the European Commu-
nity Council on animal care.
Drugs
The following drugs were used: indomethacin (nons-
teroidal antiinflammatory drug NSAID—Sigma, Milano),
caffeine (adenosine antagonist—Sigma, Milano), prochlor-
perazine (D2-antagonist—Sigma, Milano), oxotremorine
(muscarinic agonist—Fluka, Milano), amitriptyline (tric-
yclic antidepressant—Sigma, Milano), baclofen (GABAB-
agonist—RBI, Milano), and diclofenac (NSAID—Sigma,
Milano). The doses of all the drugs used in the two
models of hyperalgesia were chosen on the basis of the
evidence that such doses are not antinociceptive both
in the hot plate test and in the 0.6% solution of acetic
acid induced abdominal constriction test. In the latter
test the nonantinociceptive doses resulted: 0.1 mg kg−1,
i.p. for indomethacin; 0.3 mg kg−1, i.p., for caffeine;
0.1 mg kg−1, i.p., for prochlorperazine; 0.01 mg kg−1,
i.p., for oxotremorine; 0.5 mg kg−1, i.p., for amitryptiline;
0.2 mg kg−1, i.p., for baclofen; and 1 mg kg−1, i.p., for
diclofenac; while indomethacin 1 mg kg−1, i.p.; caffeine
3 mg kg−1, i.p.; prochlorperazine 1 mg kg−1, i.p.; ox-
otremorine 0.04 mg kg−1, i.p.; amitryptiline 5 mg kg−1,
i.p.; baclofen 2 mg kg−1, i.p.; and diclofenac 10 mg kg−1,
i.p., were all effective.
Morphine administration schedule
Mice were randomly assigned to either the morphine-
treated group or one of two control (tap water or 5%
saccharose) groups. Morphine-treated mice received a so-
lution of morphine, dissolved in 5% saccharose solution,
in their water bottles in increasing doses as follows: days
1 and 2, 0.1 mg ml−1; days 3 and 4, 0.2 mg ml−1; days 5
and 6, 0.3 mg ml−1; days 7–15, 0.4 mg ml−1. On day 15,
the morphine and saccharose solutions were replaced with
tap water at a time referred to as 0 h. Four hours after the
replacement with water, mice showed a significant reduc-
tion of pain threshold in the hot plate test that reached the
highest intensity after 6 h (11.8±0.8 s of licking latency vs
15.7± 1.1 s in the control group). All the drugs under in-
vestigation were administered i.p. in correspondence with
their analgesic peak according to their pharmacokinetic
characteristics and in particular prochlorperazine 45 min,
indomethacin 30 min and caffeine 15 min before the sixth
hour following the morphine removal. A control group
was treated with a saline solution.
Hot plate test
The method adopted was described by O’Callaghan
and Holtzman [7]. Mice were placed inside a stainless
steel container, thermostatically set at 52.5 ± 0.1 ◦C in
a precision water-bath from KW Mechanical Workshop,
Siena, Italy. Reaction times (seconds) were measured
with a stop-watch before (pretest) and after treatment.
The endpoint used was the licking of the fore or hind
paws. Those mice scoring below 12 and over 18 s in the
pretest were rejected (30%). An arbitrary cut-off time
of 45 s was adopted. The licking latency values were
recorded at regular intervals (15 min) starting from 6 h
after morphine removal until further 30 min and the effect
of the drugs under investigation was compared versus the
saline-treated mice.
Abdominal constriction test
Mice were injected i.p. with a 0.3% solution of acetic
acid (10 ml kg−1), that is half the percentage described
by Koster et al. [8]. Caffeine was administered 10 min
before the acetic acid injection, whereas indomethacin,
oxotremorine, amitriptyline, baclofen, and diclofenac
were administered 25 min and prochlorperazine 40 min
before the acetic acid injection. The combination of in-
domethacin, caffeine, and prochlorperazine was admin-
istered 15 min before the injection of the 0.3% solution
of acetic acid. The number of stretching movements
was counted for 10 min, starting 5 min after acetic acid
injection.
Statistics
Results are given as the mean ± sem; the analysis of
variance (ANOVA) was used to verify the significance
between two means, followed by Fisher’s PLSD proce-
dure for post hoc comparison. P values of less than 0.05
were considered significant. Data were analyzed with the
StatView for the Macintosh computer program (1992).
RESULTS
Hyperalgesia induced by morphine withdrawal
Indomethacin 0.3 mg kg−1, i.p., was able to induce a sta-
tistically significant increase of pain threshold in mouse
hot plate test in hyperalgic mice after 6 h from morphine
removal in comparison with the control group (Fig. 1).
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Fig. 1. Effect of indomethacin (0.3 mg kg−1, i.p.) on hyperalgesia induced by morphine withdrawal in mouse hot plate test. Each column represents the
mean of at least 10 mice. All data are mean ± sem; (∗) P < 0.05 versus the corresponding nontreated mice (saline). () Saline and () indomethacin.
Caffeine at 0.3 mg kg−1, i.p., was able to revert morphine
withdrawal-induced hyperalgesia, with a statistically sig-
nificant increase of pain threshold at 6 h and 6 h 15 min
after morphine removal (Fig. 2). Caffeine also at the dose
of 0.1 mg kg−1, i.p., was active in this experimental model
(data not shown). Prochlorperazine 0.1 mg kg−1, i.p., in-
duced a statistically significant increase of pain threshold
at all the observation times (Fig. 3). Also the combina-
tion of indomethacin 0.3 mg kg−1, caffeine 0.1 mg kg−1,
and prochlorperazine 0.03 mg kg−1, i.p., resulted in being
able to revert morphine withdrawal-induced hyperalge-
sia (Fig. 4). The combination of indomethacin 1 mg kg−1,
caffeine 0.3 mg kg−1, and prochlorperazine 0.1 mg kg−1,
i.p., that means three times a higher dosage of the three
Fig. 2. Effect of caffeine (0.3 mg kg−1, i.p.) on hyperalgesia induced by morphine withdrawal in mouse hot plate test. Each column represents the
mean of at least 10 mice. All data are mean ± sem; (∗) P < 0.01 versus the corresponding nontreated mice (saline). () Saline and () caffeine.
active principles, was able to induce a more prolonged an-
tihyperalgic effect (data not shown).
Amitriptyline 0.5 mg kg−1, baclofen 0.2 mg kg−1, and
diclofenac 1 mg kg−1, i.p., which are analgesic drugs not
active in the resolution of migraine attack and tested as
negative reference drugs, were not able to revert morphine
withdrawal-induced hyperalgesia, while oxotremorine,
another negative reference drug, resulted able to revert
this type of hyperalgesia at the dose of 0.01 mg kg−1.
The same doses of indomethacin, caffeine, and prochlor-
perazine able to revert morphine withdrawal-induced
hyperalgesia were not able to increase the pain threshold
in mice not treated with morphine, showing that the result
was not due to an analgesic effect (Figs. 1–3).
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Fig. 3. Effect of prochlorperazine (0.1 mg kg−1, i.p.) on hyperalgesia induced by morphine withdrawal in mouse hot plate test. Each column represents
the mean of at least 10 mice. All data are mean ± sem; (∗) P < 0.01 versus the corresponding nontreated mice (saline). () Saline and ()
prochlorperazine.
Fig. 4. Effect of IndoProCaf (indomethacin 0.3 mg kg−1, caffeine 0.1 mg kg−1, and prochlorperazine 0.03 mg kg−1, i.p.) on hyperalgesia induced by
morphine withdrawal in mouse hot plate test. Each column represents the mean of at least 10 mice. All data are mean ± sem; (∗) P < 0.01 versus the
corresponding nontreated mice (saline). () Saline and () IndoProCaf.
Fig. 5. Effect of IndoProCaf (indomethacin 0.1 mg kg−1, caffeine 0.3 mg kg−1, prochlorperazine 0.1 mg kg−1, i.p.) in mouse abdominal constriction
test induced by a 0.3% solution of acetic acid. Each value represents the mean of two experiments. All data are mean± sem; (∗) P < 0.05 versus saline
controls and (◦) P < 0.01 versus indomethacin or caffeine or prochlorperazine-treated mice.
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Hyperalgesia induced by a 0.3% solution of
acetic acid
In this model the effect of the following drugs was
tested: indomethacin 0.01 and 0.1 mg kg−1, i.p.; caffeine
0.03 and 0.3 mg kg−1, i.p.; prochlorperazine 0.01 and
0.1 mg kg−1, i.p.; oxotremorine 0.001 and 0.01 mg kg−1,
i.p.; amitriptyline 0.5 e 5 mg kg−1, i.p.; baclofen 0.2 and
2 mg kg−1, i.p.; and diclofenac 0.1 and 1 mg kg−1, i.p. In-
domethacin 0.1 mg kg−1, caffeine 0.3 mg kg−1, prochlor-
perazine 0.1 mg kg−1, and diclofenac 1 and 0.1 mg kg−1
reduced the number of abdominal constrictions, while
amitriptyline and baclofen were able to reduce the number
of abdominal constrictions only at the analgesic dosage
and oxotremorine resulted active at 0.01 mg kg−1.
The combination of indomethacin 0.1 mg kg−1, caffeine
0.3 mg kg−1, and prochlorperazine 0.1 mg kg−1 resulted
able to abolish almost completely the abdominal constric-
tions, with a statistically significant difference in compar-
ison with each active principle (Fig. 5).
DISCUSSION
The aim of this study was to evaluate if indomethacin,
caffeine, and prochlorperazine alone and combined were
able to revert hyperalgesia in in vivo models of migraine.
This study showed that indomethacin, caffeine, and
prochlorperazine are all active in reverting hyperalgesia
induced both by morphine withdrawal and by a 0.3%
solution of acetic acid at doses at least 10 times lower
than the corresponding analgesic ones. It is known that
indomethacin is analgesic at the dose of 10 mg kg−1,
i.p., in the formalin test in mice [9]. According to our
experience, indomethacin is analgesic also at the dose
of 1 mg kg−1, i.p., in the 0.6% solution of acetic acid
test in mice, while it resulted in reverting hyperalgesia
at the dose of 0.1 mg kg−1, i.p., in the 0.3% solution of
acetic acid test and at the dose of 0.3 mg kg−1, i.p., in the
morphine withdrawal test. Caffeine produced significant
analgesia both in mice at the doses of 1–5 mg kg−1, s.c.
and in rats at the doses of 2.5–5 mg kg−1, i.p. [10], while
its antihyperalgic effect was evident up to 0.1 mg kg−1,
i.p. Prochlorperazine resulted analgesic at the doses of
1 and 2 mg kg−1, i.p., in mice [11], while it resulted
in reverting hyperalgesia at the dose of 0.1 mg kg−1,
i.p. Furthermore, the antihyperalgic effect of the three
active principles is not dependent on the analgesic activ-
ity of the three drugs, considering that the same doses of
indomethacin, caffeine, and prochlorperazine in reverting
morphine withdrawal induced hyperalgesia are not able
to increase the pain threshold in mice not treated with
morphine.
The results of this study also showed that the combina-
tion of indomethacin, caffeine, and prochlorperazine not
only induced a statistically significant increase of pain
threshold in the morphine withdrawal test, but was also
able to abolish almost completely the abdominal con-
strictions, with a significantly higher efficacy compared
to the single active principles. It represents a synergic
effect of the combination. It is also important to note that
the dose-ratio used for the combination in the experi-
mental models (ratio: indomethacin 1, caffeine 0.3, and
prochlorperazine 0.1) corresponds to the dose-ratio of the
therapeutic dose used in both the oral and rectal forms
of IndoProCaf, the only different ratio being caffeine
(in the experimental models a dose-ratio 10 times lower
was used). The dose range of indomethacin contained in
IndoProCaf is 25–50 mg, a lower dose compared to the
antirheumatic dosage; the range of caffeine is 75–150 mg,
while the dose range of prochlorperazine is 2–8 mg, a
lower dose compared to the antipsychotic dosage.
Drugs as amitriptyline, baclofen, and diclofenac
were not able to revert morphine withdrawal induced
hyperalgesia.
Notwithstanding the availability of the triptans since the
beginning of the 1990s, the combination of indomethacin,
caffeine, and prochlorperazine still represents nowa-
days the most popular and used antimigraine treatment
in the Italian market. All the active principles are very
well-known drugs, available world-wide on the market,
used in different indications, indomethacin as a NSAID,
caffeine in different analgesic preparations, prochlor-
perazine at high doses as an antipsychotic [12] and at
low doses as an antiemetic drug [13]. However, each
active ingredient has specific antimigraine properties. In-
domethacin showed a central analgesic activity which has
not been demonstrated for other NSAIDs and a central
vasoconstrictive activity [4, 14]. Moreover, indomethacin
is the only NSAID with a structural formula very similar to
serotonin and to the triptans. Caffeine, used as an analgesic
adjuvant [15–17], is endowed with its own central anal-
gesic cholinergic and vasoconstrictive activity [10, 18].
Prochlorperazine is effective against vomiting, typical
of migraine attacks and also has its own antimigraine
efficacy proved in a clinical trial versus metoclopramide
[13]; its analgesic effect, mediated through a central am-
plification of cholinergic transmission, was proven in
the mouse hot plate test and in the abdominal constric-
tion test [11]. The efficacy of the three active principles
alone, and in combination in the two models of hy-
peralgesia, may help to explain the clinical efficacy of
IndoProCaf in the treatment of migraine, a pathologi-
cal condition characterized by an excessive sensitivity
to pain.
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